Tuesday was a down day on Wall Street with stocks getting walloped across the board. Concerns over China's economy and the possibility that several big U.S. banks could see their credit ratings downgraded weighed on sentiment.
While the selling pressure was widespread for most of the session, healthcare stocks outperformed thanks to a few big movers.
Overnight, data from China showed exports from the world's second-largest economy fell 14.5% year-over-year in July, while imports dropped 12.4%.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
"The trade data from China was undoubtedly disappointing as it once again showed sluggish demand both domestically and externally," says Craig Erlam, senior market analyst at OANDA. China's economy is clearly in need of a boost, but it's likely authorities will engage in small, targeted measures that won't boost confidence among investors or households, Erlam adds.
Moody's lowers credit ratings for regional lenders, puts bigger banks under review
Meanwhile, Moody's Investors Services late Monday lowered the credit ratings for several regional lenders, including Pinnacle Financial Partners (PNFP, -2.1%) and M&T Bank (MTB, -1.5%). The ratings agency also said it is reviewing ratings for a number of larger U.S. banks, including Bank of New York Mellon (BK, -1.3%) and State Street (STT, -1.6%). The news sent shockwaves through the financial sector, with Goldman Sachs (GS, -2.1%) and JPMorgan Chase (JPM, -0.6%) being two of the worst Dow Jones stocks today.
"The development, which comes roughly five months after a handful of regional banks hit the skids, has sparked renewed concerns about the potential for additional bank failures and consolidations," says José Torres, senior economist at Interactive Brokers.
Additionally, the headlines hit as investors are trying to determine whether or not the Federal Reserve will continue to raise interest rates. "To that end, the Consumer Price Index (CPI) data to be released this Thursday could be a significant driver of investor sentiment and the outlook for the Fed's monetary policy," Torres adds.
Eli Lilly, Novo Nordisk pop on weight-loss drug news
Investors also took in the latest batch of earnings reports. On the positive side of the ledger, Eli Lilly (LLY) popped 14.9% after the drugmaker reported higher-than-expected second-quarter earnings of $2.11. Plus, revenue of $8.3 billion beat estimates thanks in part to strong sales of Eli Lilly's diabetes drug Mounjaro. LLY also got a boost after Novo Nordisk (NVO, +17.2%) said its obesity drug Wegovy reduced the chance of heart attacks by 20% in subjects who participated in a trial.
The data removes an "overhang" for the obesity treatment landscape, says BofA Securities analyst Geoff Meacham. The analyst, who reiterated his Buy rating on LLY, added that "today's results bolsters our confidence in the obesity commercial opportunity."
At the other end of the spectrum, Beyond Meat (BYND) tumbled 14.3% after the plant-based protein maker reported earnings. While the company reported a narrower-than-expected second-quarter loss of 83 cents per share, revenue of $102.1 million – down 30% on a year-over-year basis – came in below estimates. BYND also gave lower-than-anticipated full-year revenue guidance.
As for the major indexes, while they finished well off their intraday lows, the blue chip Dow Jones Industrial Average still closed down 0.5% to 35,314. The broader S&P 500 shed 0.4% to 4,499, and the tech-heavy Nasdaq Composite fell 0.8% to 13,884.
Related Content
-
Stock Market Today: Solid Signals Lift Stocks Despite Tariff NoiseMarkets are whistling over the White House in an ongoing display of corporate America's enduring ability to survive and advance.
-
Amtrak Joins Prime Day With Deals on Fares — But You’ll Have to Act FastPrime members can score 20% off midweek fares — what travelers should know before booking.
-
Dividend Increases: 7 Stocks With Rising PayoutsWhile dividend growth has been slowing, certain stocks have raised their dividend payouts. These are some selections.
-
Stock Market Today: Trump Reextends His Tariff DeadlineWhen it comes to this president, his trade war, the economy, financial markets and uncertainty, "known unknowns" are better than "unknown unknowns."
-
Stock Market Today: Another Quarter, More Mixed Price Action"Up and to the right" remains the general trend despite persistent uncertainty around critical policy issues.
-
Stock Market Today: Stocks Rise on Less Deadly ConcernsMarkets are forward-looking mechanisms, and it's good when price action shows there's a future to look forward to.
-
My Three-Day Rule for Investing: And If it Applies NowStock Market I've seen a lot in my career. Here's what I see now in the stock market.
-
Is It Time to Invest in Europe?Stock Market Europe is being shaken out of its lethargy, militarily and otherwise, by Donald Trump's changes in U.S. policy. Should investors start buying?
-
What Wall Street's CEOs Are Saying About Trump's TariffsWe're in the thick of earnings season, and corporate America has plenty to say about the Trump administration's trade policy.
-
Stock Market Today: Stocks Gain on Tech, Auto Tariff TalkThe Trump administration said late Friday that it will temporarily halt tariffs on some Chinese tech imports.
